Regeneron’s COVID-19 Antibody “Cocktail” Granted Emergency Use Authorization by FDA
Before patients can be treated with REGEN-COV2 under the EUA, they must weigh at least 40 kilograms (about 88 pounds) and be deemed at high risk for progressing to severe COVID-19 and/or hospitalization. That high-risk category includes adults who are ages 65 or older, or who have chronic medical conditions.
New Genetic Markers of Lung Cancer Could Lead to More Personalized Treatments
The researchers found that mutations in KMT2C and KMT2D make non-small cell lung cancer more sensitive to Poly (ADP-ribose) polymerase (PARP) inhibitors, which are already approved for treating prostate, pancreatic, ovarian, and breast cancer patients.
Risk of Lung Cancer Linked to Specific Variants
The researchers identified 25 new rare pathogenic variants associated with lung cancer susceptibility and validated five of those variants. Of those five, two variants involved genes with known connections to lung cancer risk, ATM and MPZL2. Three variants involved novel lung cancer susceptibility genes, POMC, STAU2 and MLNR.
Nebulizer Can Deliver CRISPR-Based Treatment Targeting COVID-19 and Influenza
The researchers used mRNA technology to code for Cas13a, which destroys parts of the RNA genetic code that viruses use to replicate in cells in the lungs. Using a guide strand, researchers can provide a map that basically tells the Cas13a protein where to attach to the viruses’ RNA and begin to destroy it.
Gut Microbes That Influence Neurological Disorders May Inspire New Therapies
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
Intestinal Organoids Developed to Test New Drugs for COVID-19
SARS-CoV-2 affects many parts of the body. Although the primary manifestations of COVID-19 involve the respiratory system, gastrointestinal effects may play a critical role in both disease severity and transmission.
Increasing ABCC1 Gene Expression Could Help Prevent Alzheimer’s Disease
The ABCC1 protein has the ability to break down amyloid plaques in Alzheimer’s disease and researchers show in a new study that increasing expression of this gene may even prevent the neurodegenerative disease from developing in the first place.
Metabolic Profiling for Pancreatic Cancer Predicts Patient Outcomes
A team of researchers from Centre de Recherche en Cancerologie de Marseille (CRCM), INSERM in France have developed a new method for capturing the metabolic signature of pancreatic ductal adenocarcinoma to predict clinical outcomes.
Direct RNA Amplification Reagents
The new automation friendly reagents allow laboratories testing for COVID-19 have a tool that allows them to skip the RNA extraction step of the many testing workflows and move directly to PCR amplification.
New Biomarker of Pancreatic Cancer May Predict Benefit of Tumor-Penetrating Peptide
According to the new study, the tumor-penetrating peptide known as iRGD appears to enhance the effects of chemotherapy, reducing metastasis, and increasing survival, to a degree determined by levels of β5 integrin. Essentially, β5 integrin gives chemotherapeutic agents the opportunity to destroy the tumor from within.
Prime Time for the Microbiome
With some positive results in the clinic, there are other encouraging signs the field is maturing and branching into other therapeutic areas such as oncology.
RNA for Medical Analysis
From Mendelian disorders to COVID-19, academic and industrial scientists use these nucleic acids to help diagnose diseases.
Top Women in Precision Medicine
In our second installment of women making their mark in the field, Clinical OMICs interviews Bonnie Anderson of Veracyte, Tina Hambuch of Invitae, and Cindy Perettie of Foundation Medicine.
Saving Baby Nathan
California Medicaid’s pilot program Project Baby Bear delivers better outcomes at lower cost via rapid whole-genome sequencing of critically ill newborns.
Payer Policies not Sole Reason for Inconsistent Utilization of Genomic Testing
A report from the Personalized Medicine Coalition found significant variability in the use of genomic testing for patients not only from state to state, but also within states.
Latest by Topic
